As of 30 Sep 2025, 15 institutional investors reported holding $278,232,000 in principal (par value) of PTC THERAPEUTICS INC - NOTE 1.500% 9/1.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | $227,000 | $336,391 | -$87,432 | 148.19% | 1 |
| 2025 Q3 | $278,232,000 | $296,027,478 | +$13,559,252 | 128.25% | 15 |
| 2025 Q2 | $275,383,000 | $318,055,093 | -$3,252,363 | 115.48% | 15 |
| 2025 Q1 | $276,612,000 | $326,799,984 | +$764,879 | 117.03% | 14 |
| 2024 Q4 | $264,421,591 | $309,275,303 | -$20,167,920 | 111.67% | 13 |
| 2024 Q3 | $259,449,591 | $309,774,451 | +$581,700 | 103.99% | 12 |
| 2024 Q2 | $259,449,591 | $284,800,544 | +$181,861 | 95.4% | 12 |
| 2024 Q1 | $274,717,308 | $277,129,832 | -$20,916,765,817 | 93.25% | 14 |
| 2023 Q4 | $287,509,503 | $273,105,852 | +$8,064,135 | 91.88% | 14 |
| 2023 Q3 | $278,652,272 | $234,329,774 | -$14,142,683 | 79.71% | 20 |
| 2023 Q2 | $287,637,000 | $296,005,222 | +$7,205,466 | 102.75% | 19 |
| 2023 Q1 | $279,704,527 | $318,037,639 | -$1,837,820 | 113.7% | 17 |
| 2022 Q4 | $287,400,000 | $284,218,480 | -$757,125 | 98.54% | 10 |
| 2022 Q3 | $287,600,000 | $335,725,501 | +$32,236,012 | 117.17% | 11 |
| 2022 Q2 | $262,509,000 | $275,443,000 | +$275,444,375 | 104.71% | 10 |